Targeting metabolic reprogramming in chronic lymphocytic leukemia

Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of cancer, is considered as a promising therapeutic target against tumors. In chronic lymphocytic leukemia (CLL) cells, metabolic abnormalities mediate alternations in proliferation and survival compared with normal B c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Yu, Yun, Xiaoya, Zhang, Ya, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235173/
https://www.ncbi.nlm.nih.gov/pubmed/35761419
http://dx.doi.org/10.1186/s40164-022-00292-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235173/
https://www.ncbi.nlm.nih.gov/pubmed/35761419
http://dx.doi.org/10.1186/s40164-022-00292-z

Ejemplares similares